NasdaqGS:RPRXPharmaceuticals
Assessing Royalty Pharma (RPRX) Valuation After Dividend Increase And Raised Full Year Guidance
Royalty Pharma (RPRX) has drawn fresh attention after its board approved a 6.8% increase in the quarterly dividend to US$0.235 per Class A share, along with raised full year guidance following recent results.
See our latest analysis for Royalty Pharma.
The dividend increase and higher full year guidance come after a period of improving momentum, with the share price at US$40.17, a 90 day share price return of 11.55% and a 1 year total shareholder return of 39.65%, suggesting sentiment has...